{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    7,
    10,
    17,
    18,
    19,
    20,
    21,
    23,
    24,
    25,
    26,
    27,
    28,
    31
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "End of Study Definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.3",
        "sectionTitle": "Definition of end of study",
        "description": "Revised to include Post-Trial Access (PTA) program information."
      },
      {
        "id": "ref_2",
        "name": "AE Management Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.3",
        "sectionTitle": "Dose modifications and reductions",
        "description": "Table 6-8 updated to include Hemophagocytic lymphohistiocytosis (HLH) reference."
      },
      {
        "id": "ref_3",
        "name": "Pneumonitis Guidelines",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.3.3.6",
        "sectionTitle": "Table 6-13",
        "description": "Clarification of mandatory dose modifications and clinical management for pneumonitis."
      },
      {
        "id": "ref_4",
        "name": "Amylase/Lipase Management",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.3.3.11",
        "sectionTitle": "Table 6-18",
        "description": "Updated for PDR001 resumption at 2nd occurrence of grade 4 asymptomatic amylase/lipase."
      },
      {
        "id": "ref_5",
        "name": "Imaging Assessment Plan",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.2.1",
        "sectionTitle": "Table 7-4",
        "description": "Updated to include public health emergency disruption proofing language."
      },
      {
        "id": "ref_6",
        "name": "Statistical Assumptions",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.8",
        "sectionTitle": "Sample size calculation",
        "description": "Reference for statistical analysis and assumptions regarding delayed treatment effect."
      },
      {
        "id": "ref_7",
        "name": "RECIST Appendix",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "14.1",
        "sectionTitle": "Appendix 1: RECIST 1.1",
        "description": "Detailed efficacy assessment and definitions using RECIST 1.1 criteria."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "For asymptomatic amylase and/or lipase elevations refer to Table 6-18",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "6.3.3.12, Table 6-19",
        "pageNumber": 27
      },
      {
        "id": "annot_2",
        "text": "Placebo administrations to those patients randomized to the placebo arm will discontinue while dabrafenib and trametinib may continue for the same patients",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "6.5.3",
        "pageNumber": 19
      },
      {
        "id": "annot_3",
        "text": "The changes herein affect the Informed Consent. Sites are required to update and submit for approval a revised Informed Consent.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Amendment Summary",
        "pageNumber": 20
      },
      {
        "id": "annot_4",
        "text": "Language was updated to align with the latest Novartis protocol template (OneCTP version 5.0).",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Amendment 7 Rationale",
        "pageNumber": 18
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "07",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2023-01-27",
        "description": "Revised end of study definition for PTA, updated HLH safety info, and added public health emergency mitigation.",
        "amendmentNumber": "Amendment 7"
      },
      {
        "id": "ver_2",
        "versionNumber": "06",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-10-13",
        "description": "Enabled continuation following final PFS analysis to characterize OS benefit; mandatory unblinding.",
        "amendmentNumber": "Amendment 6"
      },
      {
        "id": "ver_3",
        "versionNumber": "05",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-03-08",
        "description": "Adjusted timing of final PFS analysis and included interim PFS analysis based on delayed treatment effect.",
        "amendmentNumber": "Amendment 5"
      },
      {
        "id": "ver_4",
        "versionNumber": "04",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2018-08-14",
        "description": "Aligned contraception requirements with IB updates and updated GDPR personal data definitions.",
        "amendmentNumber": "Amendment 4"
      }
    ],
    "summary": {
      "referenceCount": 7,
      "annotationCount": 4,
      "versionCount": 4
    }
  }
}